MTNB Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -- compared to Matinas BioPharma Holdings's net margin of -49.65%. Matinas BioPharma Holdings's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Matinas BioPharma Holdings has a consensus price target of --, signalling upside risk potential of 5072.41%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 44.07%. Given that Matinas BioPharma Holdings has higher upside potential than NovaBay Pharmaceuticals, analysts believe Matinas BioPharma Holdings is more attractive than NovaBay Pharmaceuticals.

Matinas BioPharma Holdings has a beta of 1.363, which suggesting that the stock is 36.292% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.271%.

Matinas BioPharma Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Matinas BioPharma Holdings pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Matinas BioPharma Holdings quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Matinas BioPharma Holdings's net income of -$4.3M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Matinas BioPharma Holdings's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Matinas BioPharma Holdings is 0.63x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Retractable Technologies has a net margin of -- compared to Matinas BioPharma Holdings's net margin of -18.58%. Matinas BioPharma Holdings's return on equity of -- beat Retractable Technologies's return on equity of -16.83%.

Matinas BioPharma Holdings has a consensus price target of --, signalling upside risk potential of 5072.41%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that Matinas BioPharma Holdings has higher upside potential than Retractable Technologies, analysts believe Matinas BioPharma Holdings is more attractive than Retractable Technologies.

Matinas BioPharma Holdings has a beta of 1.363, which suggesting that the stock is 36.292% more volatile than S&P 500. In comparison Retractable Technologies has a beta of 2.279, suggesting its more volatile than the S&P 500 by 127.852%.

Matinas BioPharma Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Matinas BioPharma Holdings pays -- of its earnings as a dividend. Retractable Technologies pays out -1.94% of its earnings as a dividend.

Matinas BioPharma Holdings quarterly revenues are --, which are smaller than Retractable Technologies quarterly revenues of $10.3M. Matinas BioPharma Holdings's net income of -$4.3M is lower than Retractable Technologies's net income of -$1.9M. Notably, Matinas BioPharma Holdings's price-to-earnings ratio is -- while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Matinas BioPharma Holdings is 0.63x versus 0.64x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Stereotaxis has a net margin of -- compared to Matinas BioPharma Holdings's net margin of -118.53%. Matinas BioPharma Holdings's return on equity of -- beat Stereotaxis's return on equity of -139.2%.

Matinas BioPharma Holdings has a consensus price target of --, signalling upside risk potential of 5072.41%. On the other hand Stereotaxis has an analysts' consensus of $4.50 which suggests that it could grow by 155.68%. Given that Matinas BioPharma Holdings has higher upside potential than Stereotaxis, analysts believe Matinas BioPharma Holdings is more attractive than Stereotaxis.

Matinas BioPharma Holdings has a beta of 1.363, which suggesting that the stock is 36.292% more volatile than S&P 500. In comparison Stereotaxis has a beta of 1.602, suggesting its more volatile than the S&P 500 by 60.223%.

Matinas BioPharma Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Matinas BioPharma Holdings pays -- of its earnings as a dividend. Stereotaxis pays out -- of its earnings as a dividend.

Matinas BioPharma Holdings quarterly revenues are --, which are smaller than Stereotaxis quarterly revenues of $6.3M. Matinas BioPharma Holdings's net income of -$4.3M is higher than Stereotaxis's net income of -$7.5M. Notably, Matinas BioPharma Holdings's price-to-earnings ratio is -- while Stereotaxis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Matinas BioPharma Holdings is 0.63x versus 5.57x for Stereotaxis. Usually stocks with elevated PS ratios are considered overvalued.